Understanding the TLR7 Signature in TNBC

Triple-negative breast cancer (TNBC) represents a highly aggressive malignancy with limited therapeutic options. Recent research highlights the TLR7 signature in TNBC as a key driver of tumour innervation and disease progression. By analyzing multiple datasets, scientists have uncovered how non-canonical TLR7 signalling influences clinical outcomes. Consequently, this signature provides a roadmap for understanding the biological diversity of breast cancer subtypes.

Identifying the TLR7 Signature in TNBC Pathways

The study delineates two distinct routes for TNBC progression based on TLR7 expression levels. High TLR7 scores characterize basal- and mesenchymal-like tumours, which often show enrichment in neuronal and mast cell-related pathways. In contrast, TLR7-low tumours exhibit increased estrogen receptor (ER) signalling and T cell-associated pathways. Therefore, these findings effectively distinguish between innervated and non-innervated TNBC phenotypes.

Prognostic Outcomes and Patient Stratification

Interestingly, the TLR7 signature in TNBC does not follow a simple linear correlation with survival. Data from seven independent clinical cohorts show that both high-score and low-score tumours associate with unfavourable outcomes. Intermediate scores, however, suggest a relatively better prognosis. Furthermore, the signature correlates with pathological complete response (pCR) in a manner that depends on the specific treatment regimen.

Molecular Drivers of Aggressive Disease

Specifically, TLR7-high lesions frequently involve the loss of RB1 and TP53. These tumours also demonstrate elevated signalling in the PI3K, MET, and MYC pathways, which facilitate rapid cell proliferation. Moreover, the presence of neuronal elements within the tumour microenvironment actively modulates these oncogenic processes. Thus, targeting the neural components of the tumour could offer a novel strategy for precision medicine.

FAQs

What does the TLR7 signature indicate in breast cancer?

The TLR7 signature acts as a molecular marker for tumour innervation, revealing how nerves within the tumour microenvironment drive cancer growth and metastasis via non-canonical signalling.

How does TLR7 expression affect TNBC subtypes differently?

High TLR7 expression typically occurs in basal- and mesenchymal-like TNBC, which are highly aggressive. Conversely, low TLR7 expression links to the luminal androgen receptor (LAR) subtype and stronger ER signalling.

Can the TLR7 score predict treatment response?

Yes, research indicates that the TLR7 score correlates with pathological complete response (pCR), suggesting it may help clinicians select the most effective therapeutic strategies for individual patients.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wang DY et al. TLR7 signature of tumour innervation reveals two distinct pathways of triple-negative breast cancer progression. Br J Cancer. 2026 Apr 16. doi: 10.1038/s41416-026-03419-9. PMID: 41986661.

GeneOnline News. Study Identifies Role of Tumor Innervation and TLR7 Pathways in Triple-Negative Breast Cancer Progression. 2026.

Padmanaban et al. Sensory nerves unlock the TOLL-7 gate for cancer spread. PMC NIH. 2024. doi: 10.1038/s41586-024-07767-5.